about
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisThe effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trialMechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes.A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target RangesEffects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetesEffect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials.Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.A 25-year-old woman with type 2 diabetes and liver disease.Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies.Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report.The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trialsEffect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose MetabolismDialysis-Requiring Acute Kidney Injury in Denmark 2000-2012: Time Trends of Incidence and Prevalence of Risk Factors-A Nationwide StudyRisk stratification by endocrinologists of patients with type 2 diabetes in a Danish specialised outpatient clinic: a cross-sectional studyTrends in One-Year Outcomes of Dialysis-Requiring Acute Kidney Injury in Denmark 2005-2012: A Population-Based Nationwide Study.IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma.Glucagon-like peptide-1, glucose homeostasis and diabetes.Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus.The incretin system and its role in type 2 diabetes mellitus.Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetesIncretin-based therapy of type 2 diabetes mellitus.Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.Incretin-based therapies: viewpoints on the way to consensus.Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.Lixisenatide for type 2 diabetes mellitus.Emerging GLP-1 receptor agonists.The effect of glucagon-like peptide 1 on cardiovascular risk.Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.Exenatide: pharmacokinetics, clinical use, and future directions.The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.Cardiovascular safety and benefits of GLP-1 receptor agonists.
P50
Q28553482-D64BC174-C435-477F-8801-56F5798DD051Q30556651-974D146D-175E-4C0A-82D2-E531F723BB7CQ31137356-AF97B8DC-95FC-4D4D-B601-014932E301E1Q33588613-AE2BA458-4338-4534-8079-7B43CAFEBFB1Q34124353-765A3521-2D2A-46C2-A542-700F9623AEC1Q34363662-88B7CB8F-CB91-4BB9-B8ED-5D758B00E8A0Q34475476-F835820F-5A89-4818-86E0-16B5CF86D217Q34540403-D8C96AEC-90B3-4FF0-9D43-CDEFE44CADD6Q34620479-9B3B585B-D197-4F46-993E-CC741896A53BQ34975050-EEAB1B48-12F8-4058-BAD4-0C198352CA62Q34987722-7CB44CA7-E0BA-4D24-9E06-98162E278BE9Q34996877-5E80B570-25C7-4BB8-A1FB-411FC8F0E9E7Q35178140-E6DE59FB-6FCE-497F-B948-605C43654DB2Q35260544-B7A1D09A-87C2-48A2-A386-EFB3DA8E33E6Q35839938-C02C10DF-E6A1-4A16-A781-C7B0E4D24702Q35919539-B0DD049D-04AC-4B07-AD2B-830E69FC038FQ35984675-A41EA7A5-54C4-4D88-B0F7-51ADB54A9D78Q36085952-AC8B64AF-F5D1-46A0-9DF2-D64618C92EF9Q36360100-D5F979A6-D7F0-4663-A7B7-17EEF96412AFQ36712701-B87115AC-1BE6-4A6F-A965-EE123FA00D00Q36715772-8E08CA95-1634-40E7-8EC3-2ACC7385A4F1Q36783856-E3715644-0DA3-41D0-8E20-4D5F227842FFQ37009157-F6FC4504-31AE-4E49-A5A1-C555859241DEQ37114343-142AA741-2FDA-48C0-8D2B-5BF5E1F9C855Q37210486-E076F674-4E67-4B4D-B8AB-E8E313904892Q37266863-075AD372-FD7E-44A3-ABFB-6906D2B95B1BQ37278695-B0B7A308-3E8F-435B-AB58-03BA2329E26FQ37411508-F6948AB6-CD5F-4F0C-B8EF-50F92F753F1FQ37526578-700F1CC9-2863-4DA3-B36D-105A4D187B89Q37595937-7E27A018-2643-4641-BACD-217CD009D5CDQ37624267-E519386B-5AB2-4818-BFFD-AE68099EF1FFQ37684797-AAF8AE0C-23C7-4422-B770-315FA8CB016EQ37851499-74FEEAEA-275A-47A4-9E37-DBF4EBD6F4D1Q37929744-6016FF55-1E9F-41C7-9A8C-C6BBD8D196C3Q37980019-305D8932-C341-42BD-A3EE-9E524E60A26AQ38264360-168EBDAA-73E8-4472-9FB9-3CEFEE6B1842Q38393753-1BA4A5A0-B5A1-412B-9DAA-2996C9B1D73EQ38770746-16417C5E-3AAD-4BA0-BC4B-6114C0DD4DC3Q38793748-763FBD3B-7FED-49FD-A3B0-592D7EF71AE8Q39013056-D0E6F726-F28A-4611-AF7B-BF25B27B7849
P50
description
researcher ORCID ID = 0000-0002-0456-6787
@en
name
Tina Vilsbøll
@ast
Tina Vilsbøll
@en
Tina Vilsbøll
@es
Tina Vilsbøll
@nl
type
label
Tina Vilsbøll
@ast
Tina Vilsbøll
@en
Tina Vilsbøll
@es
Tina Vilsbøll
@nl
prefLabel
Tina Vilsbøll
@ast
Tina Vilsbøll
@en
Tina Vilsbøll
@es
Tina Vilsbøll
@nl
P214
P21
P214
P31
P496
0000-0002-0456-6787
P735
P7859
viaf-202779298